ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
02/04/2025
Voltar para busca
Dado oficial do USPTO
ABKIBIT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
28
Atualização mais recente
03/04/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
01/09/2020
Data de registro
13/09/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/09/2022
Última transação
03/04/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Suzhou, Jiangsu, CN
Examinador
HISER, CHARLES
Unidade examinadora
O20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
ASCENTAGE PHARMA (SUZHOU) CO., LTD.
ASCENTAGE PHARMA (SUZHOU) CO., LTD.
ASCENTAGE PHARMA GROUP CORP LIMITED
Representantes
Kathryn E. Smith WOOD HERRON & EVANS LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for dental purposes; Chemical preparations for medical purposes for treating cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Antibiotics; Injectable medicines for treating cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Medicine in tablet form for treating cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Drugs sold in bulk for treating cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Biochemical medicines for use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Antiseptics; Collyrium; Hemorrhoidal suppositorieslaxative suppositoriesvaginal suppositories for the prevention and treatment of infections; Medical pastermedical plasters; Diagnostic preparations for medical purposes; Diagnostic biomarker reagents for medical purposes; Medicated sweets; Candy for medical purposes; Dietetic foods adapted for medical purposes; Dietetic beverages adapted for medical purposes; Dietetic preparations adapted for medical purposes; Medicinal oils; Mineral food supplements; Nutritional supplements; Medicines for human purposes for use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Bacterial poisons; Pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Chemico-pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Drugs for medical purposes in the nature of prescription apoptosis targeted compoundsnext-generation kinase inhibitors and senolytic drugs; Biological preparations for medical purposesbiological preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Chemical preparations for pharmaceutical purposesfor use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Radioactive substances for medical purposes; Gases for medical purposesnitric oxide for medical purposes; Chemical conductors for electrocardiograph electrodes; Semen for artificial insemination; Disinfectants; Solutions for contact lenses; Media for bacteriological cultures; Depuratives for the body; Diagnostic preparations for veterinary purposes; Pesticides; Sanitary napkins; Cotton for medical purposes; Dental abrasives; Diapers for pets
Publicações
Histórico de despachos e eventos da marca no USPTO.
28 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
13/09/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
13/09/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/06/2022
PUBO
PUBLISHED FOR OPPOSITION
28/06/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/06/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/05/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/05/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/05/2022
ALIE
ASSIGNED TO LIE
16/05/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
11/05/2022
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
01/12/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
01/12/2021
CNSI
SUSPENSION INQUIRY WRITTEN
01/12/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
24/11/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
24/05/2021
GNSL
LETTER OF SUSPENSION E-MAILED
24/05/2021
CNSL
SUSPENSION LETTER WRITTEN
24/05/2021
DOCK
ASSIGNED TO EXAMINER
12/05/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/03/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/01/2021
GNRT
NON-FINAL ACTION E-MAILED
08/01/2021
CNRT
NON-FINAL ACTION WRITTEN
08/01/2021
DOCK
ASSIGNED TO EXAMINER
05/01/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/10/2020
NWAP
NEW APPLICATION ENTERED
04/09/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ABKIBIT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.